SCHEMBL2109908

SCHEMBL2109908

C[Si](C)(Cc1ccc(F)cc1)CN1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.46
SIGMAR1 Q99720 1/20 0.44
ALDH1A1 P00352 6/20 0.44
HTT P42858 1/20 0.44
MCHR1 Q99705 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
SCN5A Q14524 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5673726 0.98 HRH3 (0.44) HRH3SIGMAR1ALDH1A1HTTMCHR1
SCHEMBL7333053 0.98 SIGMAR1 (0.45) HRH3SIGMAR1ALDH1A1HTTMCHR1
Hydrochloric Acid SCHEMBL7338771 0.97 SIGMAR1 (0.44) HRH3SIGMAR1ALDH1A1HTTMCHR1
Hydrochloric Acid SCHEMBL7339147 0.85 KMT2A (0.49) HRH3SIGMAR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7337477 0.84 SLC6A2 (0.44) HRH3SIGMAR1
SCHEMBL10693219 0.83 HRH3 (0.46) HRH3ALDH1A1HTTSMN1; SMN2HRH4
Hydrochloric Acid SCHEMBL7336348 0.83 HRH3 (0.46) HRH3SIGMAR1ALDH1A1SMN1; SMN2HRH4
Hydrochloric Acid SCHEMBL7337646 0.83 SLC6A2 (0.43) HRH3SIGMAR1
Hydrochloric Acid SCHEMBL7331038 0.82 ALDH1A1 (0.61) HRH3SIGMAR1ALDH1A1MCHR1SMN1; SMN2
SCHEMBL7332439 0.81 SCN5A (0.51) HRH3SIGMAR1HTTSCN5AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-1677787-B1 COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR ACTIVE SUBSTANCES INFLUENCING SODIUM CHANNELS IN ORDER TO TREAT PAINFUL CONDITIONS MEDA PHARMA GMBH & CO KG (DE) 2012-12-12 EP claimed
US-20100323987-A1 COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2010-12-23 US claimed
US-7799832-B2 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2010-09-21 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-1871000-B Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain VALEANT PHARMACEUTICALS NORTH 2010-06-09 CN claimed
US-20090176814-A1 COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1871000-A Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain VALEANT PHARMACEUTICALS NORTH (DE) 2006-11-29 CN claimed
EP-1682137-A1 COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAIN Valeant Pharmaceuticals North America (US) 2006-07-26 EP claimed
WO-2005039577-A1 COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAIN VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2005-05-06 WO claimed
US-20050090547-A1 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains LABORATOIRE CHAUVIN S.A.S. (FR) 2005-04-28 US claimed
US-20050089559-A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains VALEANT PHARMACEUTICALS NORTH AMERICA 2005-04-28 US claimed
EP-0468825-B1 Organosilane derivatives, pharmaceutical compositions containing them and process for preparing same RICHTER GEDEON VEGYESZET (HU) 1997-01-08 EP claimed
US-5340823-A Administering a muscle relaxants for treating parkinson*s disease RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1994-08-23 US claimed
US-5198446-A Muscle Relaxants RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1993-03-30 US claimed
EP-0468825-A1 Organosilane derivatives, pharmaceutical compositions containing them and process for preparing same Richter Gedeon Vegyészeti Gyár R.T. (HU) 1992-01-29 EP claimed